Board of Directors

Board member since: 2017, member of the Remuneration Committee.

Born: 1979

Nationality: Swedish

Education: MSc Industrial Management & Engineering.

Other assignments: BoD Member Mallax Pharmaceuticals, Lowenco, Tandlaegen.dk, Vaccin Direkt, Avia Pharma, Impilo AB.

Experience: 15 years in private equity investing (Altor 2009–2017, Impilo 2017- current), 5 years in consulting in Boston Consulting Group (2004- 2009). Prior member of the BoD of NutraQ and Orchid Orthopedics.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: No

Board member since: 2024

Born: 1956

Nationality: Swedish

Education: Ph.D. in Neuroscience from Karolinska Institutet.

Other assignments: Board chairman of Asker Healthcare and Intervacc. Board member in Bonesupport. Partner at Tellacq Partners. Advisor to Rothschild private equity.

Experience: CEO Nycomed and board member in Alere, Coloplast, Danisco, Lundbeck and Swedish Orphan Biovitrum.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: No

Board Member since: 2021

Born: 1967

Nationality: British

Education: BSc, Hons Pharmacology, University College London.

Other assignments: Chair of Resolution Therapeutics Ltd, Board Member of Ascendis Pharma AS, Dechra Pharmaceuticals Plc, Acacia Health Ltd. Advisor at Syncona Ltd and DRI Capital. Trustee at Centre for Disease Analysis Foundation.

Experience: President International and Chief Commercial and Corporate Affairs Officer for Intercept Pharma ceuticals Inc., Senior roles at Gilead Sciences including VP Head Inter national Government Affairs, VP Head International Launch Planning HCV, and VP Head Northern Europe. Senior roles at GSK plc and Sanofi.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes

Board member since: 2024

Born: 1992

Education: A.B., with honors, in Neurobiology, Harvard University

Other assignments: Board Director or Observer for Biosynth, Cordis, Dawn Bio, Gamma Biosciences, Headlands Research, Nordic Bioscience, Precipart, Resolian, Sapphiros, and Zeus Health.

Experience: Member of the Health Care Strategic Growth team within the KKR's Americas Private Equity platform, FFL partners, The Blackstone Group

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: No

Board member since: 2024

Born: 1986

Nationality: British

Education: M.A. (First Class Hons) in Physical Natural Sciences (Chemistry) from the University of Cambridge

Other assignments: Board Member of Argenta, Nordic Biosciences, Dawn Biopharma, Biosynth Carbosynth, Alliance Pharma, Clinisupplies, Gamma Biosciences and Replay

Experience: Head of KKR’s Health Care Strategic Growth business in Europe, Goldman Sachs, member of the UK mergers & acquisitions team

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: No

Board member since: 2018

Born: 1974

Nationality: Swedish

Education: MD, Uppsala University, Registered physician; BSc, Inter national Economics and Business Administration, Uppsala University.

Other assignments: Board Member: Egetis Therapeutics AB (publ), TTM Holdco AB; Vlast AB; Greblaw AB; Board member and CEO: Cetoros AB. Board Member Akriam Therapeutics AB. 

Experience: Medical Doctor, St Görans Hospital and Uppsala University Hospital; Strategy Consultant, Boston Consulting Group; Head of New Products and BD&L, Novartis Nordics; EVP Head of Business Development and Strategy, Swedish Orphan International and Sobi; Founder and CEO, Medical Need Europe; Co founder, Wilson Therapeutics; Founder and CEO, Rare Thyroid Therapeutics;

Previous Board assignments: Wilson Therapeutics AB, OxThera AB.

Independent of the company and its executive management: Yes

Independent in relation to major shareholders of the Company: Yes